NCT06574568 - A Study of YKST02 in Participants with Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 14, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

DRUG

YKST02

BCMA-CD3 bispecific antibody

Trial Locations (12)

100024

RECRUITING

Beijing Chao-yang Hospital, Capital Medical University, Beijing

100035

RECRUITING

Beijing Jishuitan Hospital, Capital Medical University, Beijing

116001

RECRUITING

Affiliated Zhongshan Hospital of Dalian University, Dalian

150081

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

250117

NOT_YET_RECRUITING

Shandong Cancer Hospital, Jinan

310003

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

450003

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

510289

NOT_YET_RECRUITING

Sun Yat-sen Memorial Hospital, Guangzhou

528308

RECRUITING

Shunde Hospital of Southern Medical University, Foshan

530021

NOT_YET_RECRUITING

Guangxi Medical University Cancer Hospital, Nanning

030013

NOT_YET_RECRUITING

Shanxi Cancer hospital, Taiyuan